RE: Interpreting IOV

From: Mats Karlsson Date: September 16, 2005 technical Source: cognigencorp.com
From: "Mats Karlsson" mats.karlsson@farmbio.uu.se Subject: RE: [NMusers] Interpreting IOV Date: Fri, 16 Sep 2005 08:20:46 +0200 Dear Pete, It would be easier to say if something about the drug and study population and study circumstances was known. Changing protein binding or blood composition (w/ or w/o food), and different levels of physical activity could be explanations. On the other hand it could always be modeling nonsense. Best regards, Mats -- Mats Karlsson, PhD Professor of Pharmacometrics Div. of Pharmacokinetics and Drug Therapy Dept. of Pharmaceutical Biosciences Faculty of Pharmacy Uppsala University Box 591 SE-751 24 Uppsala Sweden phone +46 18 471 4105 fax +46 18 471 4003 mats.karlsson@farmbio.uu.se
Sep 15, 2005 Peter Bonate Interpreting IOV
Sep 15, 2005 Juan Jose Perez Ruixo RE: Interpreting IOV
Sep 16, 2005 J Bulitta Re: Interpreting IOV
Sep 16, 2005 Mats Karlsson RE: Interpreting IOV
Sep 16, 2005 Mark Sale Re: Interpreting IOV
Sep 16, 2005 Jeffrey A Wald Re: Interpreting IOV